Lezama E J, Konkar A A, Salazar-Bookaman M M, Miller D D, Feller D R
Facultad de Farmacia, Universidad Central de Venezuela, Caracas, Venezuela.
Eur J Pharmacol. 1996 Jul 11;308(1):69-80. doi: 10.1016/0014-2999(96)00236-1.
The chemical specificity for the beta-adrenoceptor mediated relaxation of rat esophageal smooth muscle was evaluated using selective and non-selective beta-adrenoceptor agonists and antagonists. Pindolol, ICI 89,406, ICI 118551 [erythro-1-(7-methylindan-4-yloxy)-3-(isopropylamine)-but an-2-ol] and the beta-adrenoceptor alkylating agent, pindobind, produced only small rightward shifts in the concentration-response curves of (-)-isoprenaline and (-)-trimetoquinol in this preparation. Rank order potency (pD2 values) of agonists was: (+/-)-trimetoquinol [1-(3',4',5'-trimethoxybenzyl)-6,7-dihydroxy-1,2,3, 4-tetrahydroisoquinoline] (8.34) = (-)-trimetoquinol (8.26) = BRL 37344 [(R* R*)-(+/-)-4-[2'-2-hydroxy 2-(3-chlorophenyl)ethylamino]propyl] phenoxyacetic acid] (8.16) = ICID7114 [(S)-4-(2-hydroxy- 3-phenoxy-propylamino-ethoxy)-N-(2-methoxyethyl) phenoxyacetamide] (8.03) > or = (-)-isoprenaline (7.82) > 3',5'-diiodotrimetoquinol [1-(3',5'-diiodo-4'-methoxybenzyl)-6, 7-dihydroxy-1,2,3,4-tetrahydroisoquinoline] (7.28) > 3'-iodotrimetoquinol [1-(3'-iodo-4',5'-dimethoxybenzyl)-6, 7-dihydroxy-1,2,3,4-tetrahydroisoquinoline] (7.04) > ractopamine (6.84) = 5,8-difluorotrimetoquinol [5,8-difluoro-6,7-dihydroxy-1- (3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline] (6.82) > 8-fluorotrimetoquinol [6,7-dihydroxy-8-fluoro-1-(3',4',5'- trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline] (6.56) > or = (-)-noradrenaline (6.46) > or = (-)-adrenaline (6.36) > (+/-)-noradrenaline (6.24) > (+/-)-adrenaline (6.00) > clenbuterol (5.83) > (-)-1-benzyl-6, 7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (5.75). Isomeric activity ratios of trimetoquinol isomers [(-)-(S)- > > (+)-(R)-] in esophageal smooth muscle in the presence and absence of 1 microM pindolol were 1995- and 2951-fold, respectively; and were much greater than those in rat atria (282-fold) and rat trachea (107-fold). The atypical beta/beta 3-adrenoceptor partial agonist, ICI D7114, produced concentration-dependent rightward shifts of the concentration-response curves of (-)-isoprenaline, (-)-trimetoquinol and the reference atypical beta/beta 3-adrenoceptor agonist, BRL 37344. Schild plot analysis of ICI D7114 against trimetoquinol gave slope and pA2 values of 0.91 and of 7.9, respectively. These results clearly demonstrate that the relaxant effects of these agonists in rat esophageal smooth muscle are primarily mediated through the activation of atypical beta/beta 3-adrenoceptors. (-)-Trimetoquinol was as potent as (-)- isoprenaline and BRL 37344, and was the most stereoselective agonist evaluated in this tissue system.
使用选择性和非选择性β-肾上腺素能受体激动剂及拮抗剂,评估了β-肾上腺素能受体介导的大鼠食管平滑肌舒张的化学特异性。吲哚洛尔、ICI 89,406、ICI 118551 [赤式-1-(7-甲基茚满-4-基氧基)-3-(异丙胺)-丁醇-2] 以及β-肾上腺素能受体烷基化剂平多宾,在此制剂中仅使 (-)-异丙肾上腺素和 (-)-曲美托喹酚的浓度-反应曲线产生微小右移。激动剂的效价顺序(pD2值)为:(±)-曲美托喹酚 [1-(3',4',5'-三甲氧基苄基)-6,7-二羟基-1,2,3,4-四氢异喹啉] (8.34) = (-)-曲美托喹酚 (8.26) = BRL 37344 [(RR)-(±)-4-[2'-2-羟基-2-(3-氯苯基)乙氨基]丙基]苯氧基乙酸] (8.16) = ICID7114 [(S)-4-(2-羟基-3-苯氧基丙基氨基乙氧基)-N-(2-甲氧基乙基)苯氧基乙酰胺] (8.03) ≥ (-)-异丙肾上腺素 (7.82) > 3',5'-二碘曲美托喹酚 [1-(3',5'-二碘-4'-甲氧基苄基)-6,7-二羟基-1,2,3,4-四氢异喹啉] (7.28) > 3'-碘曲美托喹酚 [1-(3'-碘-4',5'-二甲氧基苄基)-6,7-二羟基-1,2,3,4-四氢异喹啉] (7.04) > 莱克多巴胺 (6.84) = 5,8-二氟曲美托喹酚 [5,8-二氟-6,7-二羟基-1-(3',4',5'-三甲氧基苄基)-1,2,3,4-四氢异喹啉] (6.82) > 8-氟曲美托喹酚 [6,7-二羟基-8-氟-1-(3',4',5'-三甲氧基苄基)-1,2,3,4-四氢异喹啉] (6.56) ≥ (-)-去甲肾上腺素 (6.46) ≥ (-)-肾上腺素 (6.36) > (±)-去甲肾上腺素 (6.24) > (±)-肾上腺素 (6.00) > 克仑特罗 (5.83) > (-)-1-苄基-6,7-二羟基-1,2,3,4-四氢异喹啉 (5.75)。在存在和不存在1 μM吲哚洛尔的情况下,曲美托喹酚异构体在食管平滑肌中的异构活性比 [(-)-(S)- >> (+)-(R)-] 分别为1995倍和2951倍;且远大于在大鼠心房(282倍)和大鼠气管(107倍)中的活性比。非典型β/β3-肾上腺素能受体部分激动剂ICI D7114使 (-)-异丙肾上腺素、(-)-曲美托喹酚以及参考非典型β/β3-肾上腺素能受体激动剂BRL 37344的浓度-反应曲线产生浓度依赖性右移。ICI D7114对曲美托喹酚的希尔德图分析得出斜率和pA2值分别为0.91和7.9。这些结果清楚地表明,这些激动剂在大鼠食管平滑肌中的舒张作用主要是通过激活非典型β/β3-肾上腺素能受体介导的。(-)-曲美托喹酚与 (-)-异丙肾上腺素和BRL 37344一样有效,并且是在此组织系统中评估的最具立体选择性的激动剂。